Revenues - Schedule of Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Disaggregation of Revenue [Line Items]
Total revenues	$ 897,841	$ 901,983
United States
Disaggregation of Revenue [Line Items]
Total revenues	797,945	808,214
Europe
Disaggregation of Revenue [Line Items]
Total revenues	83,607	71,355
All other
Disaggregation of Revenue [Line Items]
Total revenues	16,289	22,414
Product sales, net
Disaggregation of Revenue [Line Items]
Total revenues	839,418	842,102
Total Neuroscience
Disaggregation of Revenue [Line Items]
Total revenues	605,189	580,983
Xywav
Disaggregation of Revenue [Line Items]
Total revenues	344,804	315,300
Xyrem
Disaggregation of Revenue [Line Items]
Total revenues	37,241	64,232
Epidiolex/Epidyolex
Disaggregation of Revenue [Line Items]
Total revenues	217,737	198,716
Sativex
Disaggregation of Revenue [Line Items]
Total revenues	5,407	2,735
Total Oncology
Disaggregation of Revenue [Line Items]
Total revenues	229,447	257,549
Rylaze/Enrylaze
Disaggregation of Revenue [Line Items]
Total revenues	94,233	102,750
Zepzelca
Disaggregation of Revenue [Line Items]
Total revenues	63,033	75,100
Defitelio/defibrotide
Disaggregation of Revenue [Line Items]
Total revenues	40,662	47,676
Vyxeos
Disaggregation of Revenue [Line Items]
Total revenues	29,544	32,023
Ziihera
Disaggregation of Revenue [Line Items]
Total revenues	1,975	0
Other
Disaggregation of Revenue [Line Items]
Total revenues	4,782	3,570
High-sodium oxybate AG royalty revenue
Disaggregation of Revenue [Line Items]
Total revenues	48,946	49,947
Other royalty and contract revenues
Disaggregation of Revenue [Line Items]
Total revenues	$ 9,477	$ 9,934